Cargando…

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Young‐Woo, Yoon, Seugyun, Min, Gi June, Park, Sung‐Soo, Park, Silvia, Yoon, Jae‐Ho, Lee, Sung‐Eun, Cho, Byung‐Sik, Eom, Ki‐Seong, Kim, Yoo‐Jin, Kim, Hee‐Je, Lee, Seok, Min, Chang‐Ki, Lee, Jong Wook, Cho, Seok‐Goo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853811/ https://www.ncbi.nlm.nih.gov/pubmed/31560165 http://dx.doi.org/10.1002/cam4.2565

Ejemplares similares

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
por: Yoon, Jae‐Ho, et al.
Publicado: (2019)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis
por: Yoon, Jae-Ho, et al.
Publicado: (2023)

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Haploidentical versus Double-Cord Blood Stem Cells as a Second Transplantation for Relapsed Acute Myeloid Leukemia
por: Lee, Jong-Hyuk, et al.
Publicado: (2023)

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis
por: Yi, Jun Ho, et al.
Publicado: (2021)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?
por: Min, Gi-June, et al.
Publicado: (2022)

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R‐CHOP
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
por: Cho, Byung‐Sik, et al.
Publicado: (2019)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality
por: Yoon, Jae-Ho, et al.
Publicado: (2022)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015)

Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
por: Lee, Sung-Eun, et al.
Publicado: (2018)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission
por: Yoon, Jae-Ho, et al.
Publicado: (2016)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy
por: Lee, Joonyeop, et al.
Publicado: (2021)

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study
por: Oh, Eun-Jee, et al.
Publicado: (2021)

Long-term treatment outcome of Castleman’s disease: A real-world experience
por: Min, Gi-June, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
por: Byun, Ja Min, et al.
Publicado: (2022)

Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Prognostic Impacts of D816V KIT Mutation and Peri-Transplant RUNX1–RUNX1T1 MRD Monitoring on Acute Myeloid Leukemia with RUNX1–RUNX1T1
por: Cho, Byung-Sik, et al.
Publicado: (2021)

Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p93jletrp5bmel6gt38s5gi11n